Our Bioanalytical Department at Quinta-Analytica has expanded its analytical portfolio with a new Agilent 7850 ICP-MS system.

This addition increases our capacity for total elemental content in biological matrices and speciation analysis when coupled with HPLC, using ICP-MS as an element-specific detector.

Key applications include pharmacokinetic and bioequivalence studies of metal-based complexes or compounds used in treatments such as anemia, lung cancer, or bone cancer, as well as projects focused on various contrast agents used in imaging-based diagnostic methods.

An example of our work in this area can be found in the case study on total iron determination in human blood serum, available here.

Our analyses are routinely performed under GCP and GLP standards, with the option to provide GMP-compliant testing upon request. Currently, more than 7,000 ICP-MS analyses are scheduled through September 2025, reflecting the growing demand from our clients for advanced bioanalytical studies.

With this expanded setup, we offer for you not only increased capacity, but also faster project delivery and flexible support tailored to both early-phase studies and fully GMP-regulated programs.

 


Conscio group is a scientific service provider committed to improving the safety and quality of pharmaceuticals, food and our environment. Beyond clinical and analytical expertise, the Group offers GMP manufacturing solutions for investigational medicinal products (IMPs), as well as formulation development and technology transfer across multiple dosage forms. Learn more at www.conscio.group

Additional News

  • 17 December 2025

    PF 2026: Thank You from Quinta-Analytica

    In 2025, Quinta-Analytica continued to turn complex development challenges into tangible progress. Our PF 2026 message looks back at key milestones and thanks the partners, clients, and teams who made them possible.

  • 15 December 2025

    IVBE for locally acting drugs: insights from Conscio Science Day in Munich

    Can bioequivalence for locally acting drugs be demonstrated without a single subject in a clinical trial? Yes, if your in vitro bioequivalence (IVBE) toolkit is set up in the right way.

  • 20 November 2025

    Webinar: Streamlined Evidence Strategies for Biosimilars: Analytics, PK and Immunogenicity in focus

    On behalf of Conscio Group, we are pleased to invite you to the upcoming free educational webinar from biosimilar series.